Alnylam Pharmaceuticals enters June with a fresh tension: short sellers are quietly rebuilding positions in a stock the analyst consensus still rates a Buy — but where the share price sits $160 below the average Street target.
The repositioning story in borrowed shares is the week's most notable data point. Short interest climbed 14% over the past seven days to 4.2% of the free float — roughly 5.5 million shares on loan — after spending most of May in a range around 4.8 million shares. The move looks deliberate: the step-up began around May 26, when daily estimates jumped by around 575,000 shares in a single session. That said, the absolute level remains moderate for a large-cap biotech. Borrowing costs are extremely cheap at 0.46% annualised, barely above their 30-day floor, which tells you shorts are not paying a premium to put on these bets. Availability is loose — over 5,700% of current short interest remains available to borrow — so there is no mechanical pressure on lenders to recall shares. The borrow market is simply not stressed.
Options traders lean the other direction. The put/call ratio has drifted to 0.44, about 1.6 standard deviations below its 20-day average of 0.46 — that is the most call-heavy skew in recent memory, and a signal that options buyers are leaning bullish rather than defensive. It sits well above its 52-week low of 0.36, but the direction of travel is clearly away from protection and toward upside exposure. That divergence — shorts rebuilding quietly while options players reach for calls — makes the positioning picture genuinely ambiguous rather than one-directional.
The Street leans firmly bullish, but not without nuance. Consensus carries a Buy rating, with a mean target of $445 — a 56% premium to Tuesday's close of $286.12. That gap is wide enough to matter. Citigroup initiated coverage in mid-May at Buy with a $380 target, adding a fresh voice to the bull camp. RBC Capital trimmed its Outperform target modestly to $445 from $450 around the same time, while Wells Fargo nudged its Equal-Weight target up by $1 to $377 — a gesture that changes little. The outlier on the bear side remains Jefferies, which downgraded to Hold from Buy in March and slashed its target from $522 to $330; that call looks prescient in the context of the stock's year-to-date slide and adds legitimacy to the bear case. Bulls point to Alnylam's RNAi platform strength, a growing commercial base, and a pipeline with hypertension optionality from 2030. Bears flag competition risk, the need for continued capital deployment in clinical programmes, and a demanding valuation — EV/EBITDA running near 32x on forward estimates, with a P/E multiple of approximately 25x. EPS momentum scores at the 72nd percentile suggest the earnings revision backdrop is holding up better than the price action implies.
The institutional ownership picture is broadly stable. Capital Research holds 15.3% of shares, Fidelity (FMR) 10.6%, and BlackRock 7.8% — all three reported adding modestly in April. T. Rowe Price, which added over three million shares in the first quarter, is a notable bull. Two Sigma, the quantitative fund, added 1.4 million shares in Q1, a more tactical signal worth watching. Insider activity is minor and routine — an HR Director sold small tranches in early April at prices between $316 and $334, well above current levels. At a trade significance score of just 1-2, these carry no informational weight.
Earnings are next scheduled for August 6. The recent history is muted: the stock moved just 2.1% on the day after its most recent print in May, and slipped around 2.6% after the prior event. Five-day reactions have been similarly contained, none exceeding 3.2% in either direction. Relative to biotech peers, IONS fell 4.1% on the week and AMGN slipped 2.3% — putting ALNY's 3.2% weekly decline broadly in line with the group rather than standing out as a company-specific move.
The watch into August centres on whether the rebuilding short interest signals a genuine catalyst concern — regulatory or competitive — or simply reflects the stock's underperformance versus a broader biotech rally. At $286 with a 56% Street upside to consensus target and a short score of 40 (mid-range), the data describes a stock where conviction is pulling hard in opposite directions.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
